Patients with preexisting conditions, including heart and lung disease, are at an increased risk for severe illness secondary to SARS-CoV-2 infection and it is known that FXa may play a role in both cardiac dysfunction and acute and chronic pulmonary inflammation and fibrosis. The gene discussed is F10; the disease is fibrosis.